Insights From Technical Analysis
Manuka Resources (ASX: MKR) Pulls Back as the Restart Rally Meets Its First Real Test
Manuka Resources is retracing after its May rally as investors await production milestones. With gold processing expected in July and silver production targeted for September, the market is looking for operational results to confirm the company's restart strategy.
Inoviq (ASX: IIQ)'s Breakout Reverses Hard: IIQ Slides After EXO-OC Study Reset
Inoviq shares plunged after sample-quality issues delayed validation of its EXO-OC ovarian cancer test, despite improved algorithm performance. The sharp reversal has shifted investor focus from growth potential to execution risks, timelines, and confidence in the company’s development strategy.
Judo Capital Holding (ASX: JDO) Credit Shock: Falls Hard, but the Chart Is Now Screaming “Decision Point”
Judo Capital (ASX: JDO) has dropped sharply after a credit-quality shock, lifting cost-of-risk guidance and cutting profit forecasts. Heavy selling, oversold technicals, and weak sentiment now define the stock, though long-term growth signals remain partly intact.
Mesoblast (ASX: MSB) Shares Declined Despite Ryoncil Momentum as Investors Lock In Profits
Mesoblast (ASX: MSB) is transitioning into a commercial-stage biotech as Ryoncil® sales accelerate and its late-stage pipeline advances. While the share price has eased after a strong rally, growing revenue, improving cash flow, and multiple clinical catalysts continue to support its long-term outlook.
Artrya (ASX: AYA) Pulls Back After Testing Fresh 52-Week Highs
Artrya (ASX: AYA) is consolidating after a strong rally as investors assess its U.S. expansion, FDA progress, and commercial rollout of the AI-powered Salix platform. Despite the pullback, growing adoption and clinical milestones continue to support its long-term growth outlook.
